Basking Biosciences,Inc. is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee, of Ohio State University founded the company to commercialize aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis. Leveraging aptamer technology to improve outcomes in ischemic stroke. Our operating team co...
Basking Biosciences,Inc. is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee, of Ohio State University founded the company to commercialize aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis. Leveraging aptamer technology to improve outcomes in ischemic stroke. Our operating team combines expert scientific, clinical and drug development expertise.Basking is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.